EDITOR: | February 17th, 2015

Abattis, BioCell Product Launch at CannaCon and Update

| February 17, 2015 | No Comments
image_pdfimage_print

Abattis-Bioceuticals-200x125-1February 17, 2015 (Source: Marketwired) — Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTCQX:ATTBF) (CSE:ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce that through it’s wholly owned subsidiary, Biocell Labs, Inc., it will launch it’s first product at Cannacon (‘Devonian”).

Cannacon:

Cannacon 2015 is being held at Seattle’s Pier 91 Smith Cove Event Center on February 19-22, 2015 in Seattle Washington.

Scheduled to attend is Abattis CFO Rene David, and BioCell Labs President Brazos Minshew. Biocell labs, Inc. is a wholly-owned subsidiary of Abattis Bioceuticals Corp. Michelle’s Sexton’s Phytalab Team will also be attending, Abattis owns a 51% interest in Phytalab LLC, which is a 502 licensed Washington State Testing facility.

On display at Cannacon will be 8 phytocannabinoid formulas distributed by Abattis Bioceuticals, created by Biocell Labs, manufactured at Nature’s Formulae of Kelowna, BC, and marketed in the USA and Canada by J2Response, Bismarck North Dakota.

Formulas include ECS Supreme, a functional beverage rich in phytocannabinoids. ECS Supreme is based in Canadian Saskatoon berries and contains Abattis’ patented nitric oxide blend. Other condition-specific cannabinoid formulas presented by Abattis Bioceuticals and Biocell Labs address nausea, anxiety and Traumatic Brain Injury.

Biocell Labs and Numedica:

President of Biocell Labs (a wholly-owned subsidiary of Abattis Bioceuticals Corp), Brazos Minshew travels to Tulsa to train NuMedica opinion-leaders on the use of cannabinoids in medicine.

NuMedica is a top-tier distributor of nutraceutical remedies to physicians, pharmacists and other licensed health care providers. Their annual sales meeting is attended by their own sales team, plus physicians, pharmacists, chiropractors and naturopaths from all over North America. This year, the training will include the medical use of phytocannabinoids including CBD that are produced by Biocell Labs, Inc.

NuMedica’s “train the trainer” program will be held in Tulsa, Oklahoma February 19 – 21.

At the NuMedica forum, Biocell Labs, Inc. will launch a cannabinoid-rich product designed to address the issues of pain and inflammation. Designed to be legal in all 50 States and 10 Provinces, the phytocannabinoid product will be based in Liposomes to enhance nutrient delivery. Liposome technology is provided through an exclusive licensing agreement with Empirical Labs, Ft. Collins Colorado.

NuMedica’s vast distribution network completes the Abattis supply chain from the growers to the formulators at BioCell Labs, to the processors at Empirical Labs, to the distributors at NuMedica and, finally, to the patients who may benefit the most.

The Company would like to announce the resignation of Mr. Robert (Bob) Hedley from its Board of Directors.

Bill Fleming, Chief Executive Officer to Abattis, stated: “We would like to sincerely thank Bob for his time and many contributions to Abattis. Bob has had a significant impact while at Abattis and we are sorry to see him go from the Board, we look forward to working with his company Hedley Enterprises Ltd.”

Hedley Enterprises is a leading national distributor of natural healthfood and body care products. As a wholesaler since 1977, they supply numerous high-quality brands to healthfood stores, retail and grocery chains, greenhouse garden centers and independent health care professionals. They focus on high-quality natural and organic foods, health and beauty products and supplements with superb service.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

ON BEHALF OF THE BOARD

Bill Fleming, CEO

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.


Raj Shah

Editor:

Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>


Copyright © 2016 InvestorIntel Corp. All rights reserved. More & Disclaimer »


Leave a Reply

Your email address will not be published. Required fields are marked *